Alnylam Pharmaceuticals (ALNY) Non Operating Income (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Non Operating Income for 18 consecutive years, with -$53.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Income fell 113.6% year-over-year to -$53.6 million; the trailing twelve-month figure through Jun 2026 stood at -$275.1 million (down 65.6% YoY), and the FY2025 full-year result was -$178.4 million, up 11.01% from the prior year.
• Non Operating Income retreated to -$53.6 million in Q2 2026 per ALNY's latest filing, from -$47.0 million in the prior quarter.
• Across five years, Non Operating Income topped out at -$18.4 million in Q4 2022 and bottomed at -$147.9 million in Q3 2022.
• Historically, Non Operating Income has averaged -$56.4 million across 5 years, with a median of -$46.2 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Non Operating Income slumped 611.34% in 2022, then jumped 75.65% in 2023.
• Over 5 years, Non Operating Income stood at -$18.4 million in 2022, then fell by 15.62% to -$21.3 million in 2023, then slumped by 317.23% to -$88.8 million in 2024, then soared by 48.81% to -$45.5 million in 2025, then fell by 17.99% to -$53.6 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered -$53.6 million, -$47.0 million, and -$45.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.